Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial

Imagem de Miniatura
Arquivos
art_COLEMAN_Adjuvant_denosumab_in_early_breast_cancer_DCARE_an_2020.PDF (1.04 MB)
Citações na Scopus
154
Tipo de produção
article
Data de publicação
2020
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER SCIENCE INC
Autores
COLEMAN, Robert
FINKELSTEIN, Dianne M.
BARRIOS, Carlos
MARTIN, Miguel
IWATA, Hiroji
GLASPY, John
PERIANEZ, Alvaro Montano
TONKIN, Katia
DELEU, Ines
Citação
LANCET ONCOLOGY, v.21, n.1, p.60-72, 2020
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background Denosumab is a fully human monoclonal antibody that binds to, and inhibits, the receptor activator of RANKL (TNFSF11) and might affect breast cancer biology, as shown by preclinical evidence. We aimed to assess whether denosumab combined with standard-of-care adjuvant or neoadjuvant systemic therapy and locoregional treatments would increase bone metastasis-free survival in women with breast cancer. Method In this international, double-blind, randomised, placebo-controlled, phase 3 study (D-CARE), patients were recruited from 389 centres in 39 countries. We enrolled women (aged >= 18 years) with histologically confirmed stage II or III breast cancer and an Eastern Cooperative Oncology Group performance status of 0 or 1. On eligibility confirmation, investigators at each site telephoned an interactive voice response system to centrally randomly assign patients (1:1) based on a fixed stratified permuted block randomisation list (block size 4) to receive either denosumab (120 mg) or matching placebo subcutaneously every 3-4 weeks, starting with neoadjuvant or adjuvant chemotherapy, for about 6 months and then every 12 weeks for a total duration of 5 years. Stratification factors were breast cancer therapy, lymph node status, hormone receptor and HER2 status, age, and geographical region. The primary endpoint was the composite endpoint of bone metastasis-free survival. This trial is registered with ClinicalTrials.gov, NCT01077154. Findings Between June 2, 2010, and Aug 24, 2012, 4509 women were randomly assigned to receive denosumab (n=2256) or placebo (n=2253) and included in the intention-to-treat analysis. The primary analysis of the study was done when all patients had the opportunity to complete 5 years of follow-up with an analysis data cutoff date of Aug 31, 2017. The primary endpoint of bone metastasis-free survival was not significantly different between the groups (median not reached in either group; hazard ratio 0.97, 95% CI 0.82-1.14; p=0.70). The most common grade 3 or worse treatment-emergent adverse events, reported in patients who had at least one dose of the investigational product (2241 patients with denosumab vs 2218 patients with placebo), were neutropenia (340 [15%] vs 328 [15%]), febrile neutropenia (112 [5%] vs 142 [6%]), and leucopenia (62 [3%] vs 61 [3%]). Positively adjudicated osteonecrosis of the jaw occurred in 122 (5%) of 2241 patients treated with denosumab versus four (<1%) of 2218 patients treated with placebo; treatment-emergent hypocalcaemia occurred in 152 (7%) versus 82 (4%). Two treatment-related deaths occurred in the placebo group due to acute myeloid leukaemia and depressed level of consciousness. Interpretation Despite preclinical evidence suggesting RANKL inhibition might delay bone metastasis or disease recurrence in patients with early-stage breast cancer, in this study, denosumab did not improve disease-related outcomes for women with high-risk early breast cancer.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/34462
Referências
  1. [Anonymous], 2018, XGEVA DEN FULL PRESC
  2. Bidard FC, 2008, CLIN CANCER RES, V14, P3306, DOI 10.1158/1078-0432.CCR-07-4749
  3. Canon JR, 2008, CLIN EXP METASTAS, V25, P119, DOI 10.1007/s10585-007-9127-1
  4. Clezardin P, 2007, CLIN EXP METASTAS, V24, P599, DOI 10.1007/s10585-007-9112-8
  5. Coleman R, 2013, ANN ONCOL, V24, P398, DOI 10.1093/annonc/mds277
  6. Coleman R, 2007, CLIN BREAST CANCER, V7, pS29, DOI 10.3816/CBC.2007.s.004
  7. Coleman R, 2014, LANCET ONCOL, V15, P997, DOI 10.1016/S1470-2045(14)70302-X
  8. Colleoni M, 2000, J CLIN ONCOL, V18, P3925, DOI 10.1200/JCO.2000.18.23.3925
  9. Cronin KA, 2018, CANCER-AM CANCER SOC, V124, P2785, DOI 10.1002/cncr.31551
  10. Dhesy-Thind S, 2017, J CLIN ONCOL, V35, P2062, DOI 10.1200/JCO.2016.70.7257
  11. Early Breast Cancer Trialists' Collaborative Group, 2015, LANCET, V386, P1353, DOI 10.1016/S0140-6736(15)60908-4
  12. Gnant M, 2015, ANN ONCOL, V26, P313, DOI 10.1093/annonc/mdu544
  13. Gnant M, 2019, LANCET ONCOL, V20, P339, DOI 10.1016/S1470-2045(18)30862-3
  14. Gnant M, 2015, LANCET, V386, P433, DOI 10.1016/S0140-6736(15)60995-3
  15. Gonzalez-Suarez E, 2007, MOL CELL BIOL, V27, P1442, DOI 10.1128/MCB.01298-06
  16. Gonzalez-Suarez E, 2010, NATURE, V468, P103, DOI 10.1038/nature09495
  17. GRAY RJ, 1988, ANN STAT, V16, P1141, DOI 10.1214/aos/1176350951
  18. Hadji P, 2016, ANN ONCOL, V27, P379, DOI 10.1093/annonc/mdv617
  19. Kalbfleish JD, 1980, STAT ANAL FAILURE TI
  20. Lipton A, 2008, CLIN CANCER RES, V14, P6690, DOI 10.1158/1078-0432.CCR-07-5234
  21. Lipton A, 2007, J CLIN ONCOL, V25, P4431, DOI 10.1200/JCO.2007.11.8604
  22. Lipton Allan, 2003, Curr Treat Options Oncol, V4, P151, DOI 10.1007/s11864-003-0016-9
  23. Maurizi A, 2018, CANCERS, V10, DOI 10.3390/cancers10070218
  24. Paterson AHG, 2012, LANCET ONCOL, V13, P734, DOI 10.1016/S1470-2045(12)70226-7
  25. Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
  26. Vetter M, 2018, BREAST CANCER RES, V20, DOI 10.1186/s13058-018-1067-y
  27. von Minckwitz G, 2013, J CLIN ONCOL, V31, P3531, DOI 10.1200/JCO.2012.47.2167
  28. Zhou BQ, 2011, BIOMETRICS, V67, P661, DOI 10.1111/j.1541-0420.2010.01493.x

Coleções
Artigos e Materiais de Revistas Científicas - FM/MOG
Artigos e Materiais de Revistas Científicas - ODS/03